Arcadia Biosciences earnings release, August 13, 2026

Arcadia Biosciences, Inc. (RKDA) · Form 8-K, Item 2.02 · Filed · SEC filing

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash – – July monthly Zola® sales top $740K; exceed $1 million through first week of August – DALLAS, Texas (August 13, 2026) – Arcadia Biosciences, Inc.®

(Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2026.

“We were very pleased with our second quarter financial results,” said T.J. Schaefer, CEO of Arcadia. “Our cash used in operating activities was only $319,000 during the quarter, we have a cash balance of $4.2 million at the end of the quarter and our SG&A expenses declined by $1,000,000 versus the same period of last year, to an all-time low.”

Schaefer continued, “We believe Zola® has reached an inflection point and is now entering a new growth phase. While second quarter sales were flat compared to last year due to low inventory and shipping delays, these issues have been corrected resulting in July sales that were more than half of the sales for the entire second quarter that we are reporting today.

“In addition, after raising $4 million in gross proceeds through a private placement in June, we now have the cash to fund Zola’s growth, which we expect to accelerate as a result of new products we are bringing to market. In Q4 2026, we will launch a 1-liter espresso with a new formula that tastes more like coffee than coconut water and has pre-launch commitments from our two largest customers. In the first half of 2027, we have a plan to launch three new additional products that we are very excited about,” Schaefer added.¹

($ in thousands)

Arcadia Biosciences, Inc.

Financial Snapshot

(Unaudited)

More detailed financial information is included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under

SEC Filings.

Revenues

Revenues decreased slightly during the second quarter of 2026 compared to the same period in 2025. Zola revenues decreased $112,000, or 4%, during the first half of 2026 compared to the same period in 2025. The shortfalls in both the second quarter and first half of 2026 were primarily driven by low inventory balances and longer-than-expected shipping times.

Operating Expenses

Total operating expenses decreased slightly during the second quarter of 2026 despite a $1.0 million decrease in SG&A as 2025 operating expenses included a $1 million gain from the elimination of a contingent liability. Total operating expenses increased by $1.2 million during the first half of 2026 despite a $1.6 million decrease in SG&A due to $2.8 million in gains recognized in the first half of 2025.

Cost of revenues were essentially unchanged during the second quarter and first half of 2026 compared to the same periods in 2025.

SG&A decreased by $1.0 million and $1.6 million during the second quarter and first half of 2026, respectively, compared to the same periods in 2025, driven by lower employee costs and the absence of M&A fees in 2026.²

Other operating expenses decreased by $1.0 million during the second quarter of 2026 compared to the same period in 2025 due to a $1.0 million gain from the elimination of a contingent liability in the second quarter of 2025. Other operating expenses decreased by $2.8 million during the first half of 2026 compared to the same period in 2025 due to a $2.0 million gain from the elimination of a contingent liability as well as a $750,000 gain related to the sale of intangible assets that occurred in the first half of 2025.

Net Loss Attributable to Common Stockholders

Net loss attributable to common stockholders for the second quarter of 2026 was $6.3 million, or $2.09 per share, compared to a net loss of $4.5 million, or $3.26 per share, for the second quarter of 2025. The second quarter of 2026 included a $2.8 million unrealized loss related to the Above Food stock held by the company, a $5.4 million valuation loss relating to the company’s June 2026 PIPE financing transaction, and offering costs of $651,000, which were offset by a gain related to the change in fair value of common stock warrant and option liabilities. The second quarter of 2025 included a $4.5 million credit loss related to the note receivable from Above Food, which was offset by a $1.1 million unrealized gain related to the Above Food stock.

Net loss attributable to common stockholders for the first half of 2026 was $10.7 million, or $4.19 per share, compared to a net loss of $1.9 million, or $1.36 per share, for the first half of 2025. The first half of 2026 included a $4.3 million unrealized loss related to the Above Food stock, a $2.9 million loss on the company’s January 2026 inducement offer financing transaction, a $5.4 million valuation loss on the June 2026 PIPE, and offering costs of $1.1 million, which were offset by a $4.3 million gain related to the change in fair value of common stock warrant and option liabilities. The first half of 2025 included a $4.5 million credit loss related to the note receivable from Above Food, which was offset by a $1.1 million unrealized gain related to the Above Food stock and $1.3 million gain related to the change in fair value of common stock warrant and option liabilities.

About Arcadia Biosciences, Inc.

Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.³.fe Harbor Statement

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except share data and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:Product1,4431,4552,5432,655
Revenues:Total revenues1,4431,4552,5432,655
Operating expenses (income):Cost of revenues8128241,5121,506
Operating expenses (income):Research and development99
Operating expenses (income):Gain on sale of intangible assets-750
Operating expenses (income):Change in fair value of contingent consideration-1,000-2,000
Operating expenses (income):Selling, general and administrative1,1272,1232,3063,861
Operating expenses (income):Total operating expenses1,9391,9563,8182,626
Operating expenses (income):(Loss) Income from continuing operations-496-501-1,27529
Operating expenses (income):Interest income297216
Operating expenses (income):Credit loss-4,489-4,489
Operating expenses (income):Other (loss) income, net-2,7811,071-4,2851,071
Operating expenses (income):Loss on January 2026 Inducement Offer-2,877
Operating expenses (income):Valuation loss on June 2026 PIPE-5,423-5,423
Operating expenses (income):Change in fair value of common stock warrant and option liabilities3,083-5484,2741,314
Operating expenses (income):Issuance and offering costs-651-1,072
Operating expenses (income):Net loss attributable to common stockholders-6,266-4,458-10,651-1,859
Net loss per share attributable to common stockholders:Basic-2.09-3.26-4.19-1.36
Net loss per share attributable to common stockholders:Diluted-2.09-3.26-4.19-1.36
Weighted-average number of shares used in per share calculations:Basic2,992,5551,367,0402,540,2341,366,553
Weighted-average number of shares used in per share calculations:Diluted2,992,5551,367,0402,540,2341,366,553

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – Favorable/ (Unfavorable) – $Three Months Ended June 30, – Favorable/ (Unfavorable) – %Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – Favorable/ (Unfavorable) – $Six Months Ended June 30, – Favorable/ (Unfavorable) – %
Total revenues1,4431,455-12-1.0%2,5432,655-112-4.0%
Total operating expenses1,9391,956171.0%3,8182,626-1,192-45.0%
(Loss) income from continuing operations-496-50151.0%-1,27529-1,304-4497.0%
Net loss attributable to common stockholders-6,266-4,458-1,808-41.0%-10,651-1,859-8,792-473.0%

Balance Sheet

June 30, 2026 — (In thousands, except share data)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents4,178259
Current assets:Short-term investments4,304
Current assets:Accounts receivable and other receivables, net of allowance for credit loss of $559 as of June 30, 2026 and December 31, 2025559425
Current assets:Inventories9301,212
Current assets:Prepaid expenses and other current assets72156
Current assets:Total current assets5,7396,356
Current assets:Property and equipment, net8
Current assets:Intangible assets, net3939
Current assets:Other noncurrent assets115143
Current assets:Total assets5,8936,546
Current liabilities:Accounts payable and accrued expenses1,3831,789
Current liabilities:Other current liabilities263270
Current liabilities:Total current liabilities1,6462,059
Current liabilities:Common stock warrant and option liabilities3,614347
Current liabilities:Total liabilities5,2602,406
Stockholders’ equity:Common stock, $0.001 par value—150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 2,181,715 and 1,373,120 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively6665
Stockholders’ equity:Additional paid-in capital292,435285,292
Stockholders’ equity:Accumulated deficit-291,868-281,217
Stockholders’ equity:Total stockholders' equity6334,140
Stockholders’ equity:Total liabilities and stockholders’ equity5,8936,546

Cash Flow

Six Months Ended June 30, — (In thousands) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net loss-10,651-1,859
Adjustments to reconcile net loss to cash used in operating activities:Change in fair value of common stock warrant and option liabilities-4,274-1,314
Adjustments to reconcile net loss to cash used in operating activities:Change in fair value of contingent consideration-2,000
Adjustments to reconcile net loss to cash used in operating activities:Issuance and offering costs1,072
Adjustments to reconcile net loss to cash used in operating activities:Valuation loss on June 2026 PIPE5,423
Adjustments to reconcile net loss to cash used in operating activities:Loss on January 2026 Inducement Offer2,877
Adjustments to reconcile net loss to cash used in operating activities:Depreciation828
Adjustments to reconcile net loss to cash used in operating activities:Lease amortization117
Adjustments to reconcile net loss to cash used in operating activities:Amortization of note receivable-69
Adjustments to reconcile net loss to cash used in operating activities:Gain on sale of intangible assets-750
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to Zola products and sales, the company’s growth, cash position, operating costs, financial performance, evaluation of possible strategic alternatives and transactions, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K and in the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the company will require additional funding to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions, and may seek other strategic alternatives and transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:

T.J. Schaefer ir@arcadiabio.com

###⁴

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Arcadia Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.